CG
ABOS icon

Cutler Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Cutler Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,800
Closed -$60K – 4280
2022
Q3 		$60K Buy
+50,800
New +$291K ﹤0.01% 1763

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cutler Group's ABOS Position: Q1 2024 in Review

Cutler Group sold out of Acumen Pharmaceuticals (ABOS) in Q1 2024, closing a stake of 1,200 shares — an estimated $4K sold.

Cutler Group first reported a position in ABOS in Q4 2022 and held it in 5 quarters. The position peaked at $16K in Q4 2022. 80 funds tracked by Wall St. Rank hold ABOS as of Q1 2024.

  • Cutler Group reported no remaining Acumen Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 1,200 Acumen Pharmaceuticals shares in Q1 2024, an estimated $4K.
  • Cutler Group first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Cutler Group's Acumen Pharmaceuticals position peaked at $16K in Q4 2022.
  • 80 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.